John Sourbeer
Stock Analyst at UBS
(0.76)
# 3,906
Out of 4,959 analysts
39
Total ratings
36.84%
Success rate
-18.74%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $49.14 | +1.75% | 5 | Aug 7, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $285 → $320 | $242.63 | +31.89% | 4 | Jul 25, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $175.70 | +36.60% | 2 | Jul 25, 2025 | |
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $8.50 | +29.41% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $22.85 | +2.84% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $25.63 | +75.61% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.26 | +58.73% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $99.29 | +46.04% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $453.34 | +5.88% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $33.80 | +201.78% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $13.10 | +281.68% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $132.00 | -3.03% | 2 | Jul 27, 2022 |
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $49.14
Upside: +1.75%
West Pharmaceutical Services
Jul 25, 2025
Maintains: Buy
Price Target: $285 → $320
Current: $242.63
Upside: +31.89%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $175.70
Upside: +36.60%
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $8.50
Upside: +29.41%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $22.85
Upside: +2.84%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $25.63
Upside: +75.61%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.26
Upside: +58.73%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $99.29
Upside: +46.04%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $453.34
Upside: +5.88%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $33.80
Upside: +201.78%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $13.10
Upside: +281.68%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $132.00
Upside: -3.03%